Zealand Pharma A/S (ZLDPF)
ZLDPF Stock Price Chart
Explore Zealand Pharma A/S interactive price chart. Choose custom timeframes to analyze ZLDPF price movements and trends.
ZLDPF Company Profile
Discover essential business fundamentals and corporate details for Zealand Pharma A/S (ZLDPF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Feb 2013
Employees
385.00
Website
https://www.zealandpharma.comCEO
Adam Sinding Steensberg
Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
ZLDPF Financial Timeline
Browse a chronological timeline of Zealand Pharma A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 19 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.23.
Earnings released on 14 Aug 2025
EPS came in at $16.06 falling short of the estimated $17.22 by -6.74%, while revenue for the quarter reached $1.43B , missing expectations by -84.38%.
Earnings released on 8 May 2025
EPS came in at -$0.67 surpassing the estimated -$0.77 by +12.99%, while revenue for the quarter reached $1.19M , missing expectations by -99.98%.
Earnings released on 20 Feb 2025
EPS came in at -$0.59 surpassing the estimated -$5.30 by +88.87%, while revenue for the quarter reached $1.25M , missing expectations by -98.85%.
Earnings released on 7 Nov 2024
EPS came in at -$0.56 surpassing the estimated -$0.62 by +9.68%, while revenue for the quarter reached $649.62K , missing expectations by -97.68%.
Earnings released on 15 Aug 2024
EPS came in at -$0.67 falling short of the estimated -$0.61 by -9.84%, while revenue for the quarter reached $4.91M , beating expectations by +272.31%.
Earnings released on 16 May 2024
EPS came in at -$0.54 surpassing the estimated -$4.10 by +86.83%, while revenue for the quarter reached $2.17M , beating expectations by +76.16%.
Earnings released on 27 Feb 2024
EPS came in at -$0.66 falling short of the estimated -$0.58 by -13.79%, while revenue for the quarter reached $3.43M , beating expectations by +127.89%.
Earnings released on 9 Nov 2023
EPS came in at $0.18 surpassing the estimated -$0.53 by +133.96%, while revenue for the quarter reached $41.70M , beating expectations by +409.05%.
Earnings released on 17 Aug 2023
EPS came in at -$0.80 falling short of the estimated -$0.52 by -53.85%, while revenue for the quarter reached $1.52M , missing expectations by -15.14%.
Earnings released on 11 May 2023
EPS came in at -$0.54 surpassing the estimated -$0.54 by +0.43%, while revenue for the quarter reached $1.99M , beating expectations by +91.58%.
Earnings released on 2 Mar 2023
EPS came in at -$6.61 falling short of the estimated -$0.83 by -698.32%, while revenue for the quarter reached $3.46M , beating expectations by +162.48%.
Earnings released on 10 Nov 2022
EPS came in at -$0.45 surpassing the estimated -$0.68 by +33.82%, while revenue for the quarter reached $5.73M , beating expectations by +1.63%.
Earnings released on 11 Aug 2022
EPS came in at -$1.40 falling short of the estimated -$1.11 by -26.37%, while revenue for the quarter reached $3.98M , missing expectations by -11.39%.
Earnings released on 12 May 2022
EPS came in at -$0.63 surpassing the estimated -$0.99 by +36.07%, while revenue for the quarter reached $2.24M , missing expectations by -71.21%.
Earnings released on 10 Mar 2022
EPS came in at -$1.00 falling short of the estimated -$0.97 by -3.04%, while revenue for the quarter reached $8.23M , missing expectations by -33.74%.
Earnings released on 11 Nov 2021
EPS came in at -$0.73 , while revenue for the quarter reached $16.60M .
Earnings released on 12 Aug 2021
EPS came in at -$1.11 , while revenue for the quarter reached $13.44M .
Earnings released on 12 May 2021
EPS came in at -$0.94 , while revenue for the quarter reached $7.55M .
Earnings released on 11 Mar 2021
EPS came in at -$1.56 , while revenue for the quarter reached $10.40M .
Earnings released on 12 Nov 2020
EPS came in at -$0.90 , while revenue for the quarter reached $8.91M .
ZLDPF Stock Performance
Access detailed ZLDPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.